These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 22985897)

  • 1. Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw.
    Troeltzsch M; Woodlock T; Kriegelstein S; Steiner T; Messlinger K; Troeltzsch M
    J Can Dent Assoc; 2012; 78():c85. PubMed ID: 22985897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Non-Bisphosphonate Drugs that Produce Osteonecrosis of the Jaws.
    Ramírez L; López-Pintor RM; Casañas E; Arriba Ld; Hernández G
    Oral Health Prev Dent; 2015; 13(5):385-93. PubMed ID: 25884045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.
    Sivolella S; Lumachi F; Stellini E; Favero L
    Anticancer Res; 2013 May; 33(5):1793-7. PubMed ID: 23645723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiresorptive drug-related osteonecrosis of the jaw.
    Uyanne J; Calhoun CC; Le AD
    Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of current literature and implications of RANKL inhibitors for oral health care providers.
    Epstein MS; Ephros HD; Epstein JB
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Dec; 116(6):e437-42. PubMed ID: 22901640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
    Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
    Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab, sunitinib: osteonecrosis of the jaw.
    Prescrire Int; 2011 Jun; 20(117):155. PubMed ID: 21682016
    [No Abstract]   [Full Text] [Related]  

  • 8. Osteonecrosis of the jaw and the role of macrophages.
    Pazianas M
    J Natl Cancer Inst; 2011 Feb; 103(3):232-40. PubMed ID: 21189409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases.
    O'Halloran M; Boyd NM; Smith A
    Aust Dent J; 2014 Dec; 59(4):516-9. PubMed ID: 25131835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
    Ngamphaiboon N; Frustino JL; Kossoff EB; Sullivan MA; O'Connor TL
    Clin Breast Cancer; 2011 Aug; 11(4):252-7. PubMed ID: 21729657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
    Dodson TB
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
    Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Koerdt S; Otto S; Pautke C
    Br J Oral Maxillofac Surg; 2014 Apr; 52(4):308-13. PubMed ID: 24582013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology.
    Fusco V; Santini D; Armento G; Tonini G; Campisi G
    Expert Opin Drug Saf; 2016 Jul; 15(7):925-35. PubMed ID: 27074901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.
    Khan AA; Sándor GK; Dore E; Morrison AD; Alsahli M; Amin F; Peters E; Hanley DA; Chaudry SR; Dempster DW; Glorieux FH; Neville AJ; Talwar RM; Clokie CM; Al Mardini M; Paul T; Khosla S; Josse RG; Sutherland S; Lam DK; Carmichael RP; Blanas N; Kendler D; Petak S; St-Marie LG; Brown J; Evans AW; Rios L; Compston JE;
    J Rheumatol; 2008 Jul; 35(7):1391-7. PubMed ID: 18528958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteonecrosis of the jaw.
    Drozdzowska B
    Endokrynol Pol; 2011; 62(1):88-92. PubMed ID: 21365586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy.
    Rachner TD; Platzbecker U; Felsenberg D; Hofbauer LC
    Mayo Clin Proc; 2013 Apr; 88(4):418-9. PubMed ID: 23541016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients.
    Owosho AA; Blanchard A; Levi L; Kadempour A; Rosenberg H; Yom SK; Farooki A; Fornier M; Huryn JM; Estilo CL
    J Craniomaxillofac Surg; 2016 Mar; 44(3):265-70. PubMed ID: 26782845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports.
    Agrillo A; Nastro Siniscalchi E; Facchini A; Filiaci F; Ungari C
    Eur Rev Med Pharmacol Sci; 2012 Jul; 16(7):952-7. PubMed ID: 22953645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New oncology drugs and osteonecrosis of the jaw (ONJ).
    Migliorati CA; Covington JS
    J Tenn Dent Assoc; 2009; 89(4):36-8; quiz 38-9. PubMed ID: 20102031
    [No Abstract]   [Full Text] [Related]  

  • 20. Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect.
    Antonuzzo L; Lunghi A; Petreni P; Brugia M; Laffi A; Giommoni E; Mela MM; Mazzoni F; Balestri V; Costanzo FD
    Curr Med Chem; 2017; 24(28):3068-3076. PubMed ID: 28494743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.